Strides Arcolab surges on receiving USFDA approval for Tacrolimus Capsules

23 Jul 2014 Evaluate

Strides Arcolab is currently trading at Rs. 685.50, up by 11.30 points or 1.68% from its previous closing of Rs. 674.20 on the BSE.

The scrip opened at Rs. 651.40 and has touched a high and low of Rs. 696.00 and Rs. 651.40 respectively. So far 60425 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 696.00 on 23-Jul-2014 and a 52 week low of Rs. 233.22 on 01-Aug-2013.

Last one week high and low of the scrip stood at Rs. 696.00 and Rs. 640.65 respectively. The current market cap of the company is Rs. 4015.91 crore.

The promoters holding in the company stood at 27.67% while Institutions and Non-Institutions held 50.73% and 21.59% respectively.

Strides Arcolab has received an approval from the United States Food & Drug Administration (USFDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg. The US market for generic Tacrolimus is approximately $676 million, according to IMS data as on September 2013.

The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed directly by Strides in the US market.

Tacrolimus capsule is an immunosuppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant. It may be used along with other medicines.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

896.45 20.40 (2.33%)
30-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1502.30
Dr. Reddys Lab 6198.90
Cipla 1402.20
Zydus Lifesciences 957.00
Lupin 1645.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.